MedTrace Logo

Ex Vivo Expansion of Circulating Tumor Cells as a Model for Cancer Predictive Pharmacology

NCT03797053 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 450

Last updated 2019-01-08

No results posted yet for this study

Summary

Several studies conducted over the past decade have shown that Circulating tumor cells (CTCs) can be used as a marker for predicting disease progression and survival in patients with early or metastatic cancer. A high number of CTCs correlate with aggressive disease, increased metastasis and decreased survival rates.

Knowledge of metastasis mechanisms was mainly obtained from mouse models with CTCs after orthotopic transplants. The only possibility to study the patient's CTC subpopulations is to carry out ex-vivo expansion and develop an animal model with CTC xenograft. Because circulating blood collection is simple and non-invasive, CTCs can be used as a marker to track disease progression and survival in real time. CTCs could also guide therapeutic choice.

Conditions

Interventions

PROCEDURE

Biological sample

Biological sample performed : * before treatment * 1 months after the beginning of treatment * every tumoral assessment

Sponsors & Collaborators

  • ScreenCell

    collaborator INDUSTRY

  • Celenys

    collaborator UNKNOWN

  • Imstar

    collaborator UNKNOWN

  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-06
Primary Completion
2019-06-30
Completion
2019-06-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03797053 on ClinicalTrials.gov